A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Kannt, Aimo ^a,c   Rajagopal, Sridharan ^b   Kadnur, Sanjay Venkatachalapathi ^b   Suresh, Juluri ^b   Bhamidipati, Ravi Kanth ^b   Swaminathan, Srinivasan ^b   Hallur, Mahanandeesha Siddappa ^b   Kristam, Rajendra ^b   Elvert, Ralf ^a   Czech, Jörg ^a   Pfenninger, Anja ^a   Rudolph, Christine ^a   Schreuder, Herman ^a   Chandrasekar, Devaraj Venkatapura ^b   Mane, Vishal Subhash ^b   Birudukota, Swarnakumari ^b   Shaik, Shama ^b   Zope, Bharat Ravindra ^b   Burri, Raghunadha Reddy ^b   Anand, Niranjan Naranapura ^b   Thakur, Manish Kumar ^b   Singh, Manvi ^b   Parveen, Reejuana ^b   Kandan, Saravanan ^b   Mullangi, Ramesh ^b   Yura, Takeshi ^b   Gosu, Ramachandraiah ^b   Ruf, Sven ^a   Dhakshinamoorthy, Saravanakumar ^b   more..

^a Research and Development   (Germany)

^b JUBILANT BIOSYS LTD   (India)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; NICOTINAMIDE METHYLTRANSFERASE;

ADVERSE EVENT; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG EFFECT; ENZYMOLOGY; LIPID DIET; MALE; METABOLIC DISORDER; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ENZYME INHIBITORS; MALE; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; NICOTINAMIDE N-METHYLTRANSFERASE;

EID: 85042656753     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-22081-7     Document Type: Article

References (32)

1. Pissios, P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab 28, 340-353 (2017).
2. Aksoy, S., Szumlanski, C. L. & Weinshilboum, R. M. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J. Biol. Chem. 269, 14835-40 (1994).
3. Liu, M. et al. Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese. J. Clin. Endocrinol. Metab. 100, 3112-7 (2015).
4. Kannt, A. et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 58, 799-808 (2015).
5. Roessler, M. et al. Identification of nicotinamide-N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11, 6550-6557 (2005).
6. Kraus, D. et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508, 258-62 (2014).
7. Giuliante, R. et al. Potential involvement of nicotinamide N-methyltransferase in the pathogenesis of metabolic syndrome. Metab. Syndr. Relat. Disord. 13, 165-70 (2015).
8. Rudolphi, B. et al. Body weight predicts Nicotinamide N-methyltransferase activity in mouse fat. Endocrine Res. https://doi. org/10. 1080/07435800. 2017. 1381972 (2017).
9. Lee, Y. H. et al. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48, 1776-83 (2005).
10. Salek, R. M. et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics. 29, 99-108 (2007).
11. Hong, S. et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat. Med. 21, 887-94 (2015).
12. Neelakantan, H. et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J. Med. Chem. 60, 5015-5028 (2017).
13. van Haren, M. J. et al. Inhibitors of nicotinamide N-methyltransferase designed to mimic the methylation reaction transition state. Org. Biomol. Chem. 15, 6656-6667 (2017).
14. Ruf, S. et al. Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase. Bioorg. Med. Chem. Lett. https://doi. org/10. 1016/j. bmcl. 2018. 01. 015 (2018).
15. Rolin, B. et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 283, E745-E752 (2002).
16. Moffett, R. C., Patterson, S., Irwin, N. & Flatt, P. R. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Diab. Metab. Res. Rev. 31, 248-255 (2015).
17. Houstis, N., Rosen, E. D. & Lander, E. S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 440, 944-8 (2006).
18. Schmeisser, K. et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 9, 693-700 (2013).
19. Ulanovskaya, O. A., Zuhl, A. M. & Cravatt, B. F. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat. Chem. Biol. 9, 300-6 (2013).
20. Watanabe, C. et al. Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61, 74-84 (2012).
21. Yamada, K., Miyazaki, T., Hara, N. & Tsuchiya, M. Interferon-gamma elevates nicotinamide N-methyltransferase activity and nicotinamide level in human glioma cells. J Nutr Sci Vitaminol (Tokyo) 56, 83-86 (2010).
22. Sano, A., Endo, N. & Takitani, S. Fluorometric assay of rat tissue N-methyltransferases with nicotinamide and four isomeric methylnicotinamides. Chem Pharm Bull (Tokyo). 40, 153-6 (1992).
23. Van Haren, M. J. et al. A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase. Biochemistry. 55, 5307-15 (2016).
24. Swaminathan, S. et al. Crystal structures of monkey and mouse nicotinamide N-methyltransferase (NNMT) bound with end product, 1-methyl nicotinamide. Biochem. Biophys. Res. Commun. 491, 416-422 (2017).
25. Collaborative Computational Project. 17. The CCP4 suite: programs for protein crystallography. Acta Cryst. D 50, 760-763 (1994).
26. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Cryst. D 60, 2126-2132 (2004).
27. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst. D 53, 240-255 (1997).
28. Wlodek, S., Skillman, A. G. & Nicholls, A. Automated ligand placement and refinement with a combined force field and shape potential. Acta Cryst. D 62, 741-749 (2006).
29. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283-291 (1993).
30. DeLano, W. L. The PyMOL Molecular Graphics System. USA. (DeLano Scientific, Palo Alto, California, 2002).
31. Valenzuela, D. M. et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat. Biotechnol. 21, 652-9 (2003).
32. Neelakantan, H. et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem. Pharmacol. 147, 141-152 (2018).